Wall Street Remains Bullish on Olema Pharmaceuticals Inc. (OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the 14 best booming stocks to buy right now. On January 7, UBS initiated coverage of the stock with a Buy rating and set a $45 price target.

The update comes as part of the firm’s assumption of coverage on 22 biotech firms that have a market capitalization between $300 million and $10 billion. According to UBS, fundamentals for companies in the sector were beginning to shift after a challenging period. The analyst believes this will revive investor confidence, positioning these companies for a strong performance in 2026.

On the same day, Piper Sandler also began coverage of the stock with an Overweight rating and announced a share price target of $40. The research firm noted the potential for the company’s Palazestrant drug to become a significant endocrine treatment in the breast cancer market, which could help drive a major upside for the company.

In October last year, Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reported encouraging clinical data for the oral medication when combined with Ribociclib, with the results demonstrating promising progression-free survival and tolerability profile.

Analysts have a consensus Strong Buy rating on the stock and anticipate the share price to appreciate about 46% over the next 12 months as of January 12, reflecting Wall Street’s bullish sentiment toward the biopharmaceutical company.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused on the development of treatments for patients with breast cancer and other serious diseases. The stock has had impressive returns over the past three months, gaining 173% over the period.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.